 Nabriva Therapeutics plc NBRV, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it has entered into a definitive agreement with several healthcare-focused institutional investors, including Fidelity Management Research Company, LLC, for the purchase and sale of i an aggregate of 41,445,373 ordinary shares and ii warrants to purchase up to an aggregate of 41,445,373 ordinary shares in a registered direct offering priced at-the-market under Nasdaq rules. The gross proceeds to Nabriva Therapeutics from the offering, before deducting the placement agents fees and other estimated offering expenses payable by Nabriva Therapeutics, are approximately 38 million. 